August 2018 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2016/17 Invitation to Tender, dated 3 November 2016 and the 2017/18 Invitation to Tender, dated 2 November 2017.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2017/18 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2021
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current pack price |
New pack price |
Sole supply brand (Supplier) | Date of listing | Date of reference pricing of other listed brands | Sole Subsidised Supply date | Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
| Filgrastim | Inj 300 mcg per 0.5 ml prefilled syringe, 10 prefilled syringe | $270.00 (per 5 prefilled syringe) |
$96.22 | Nivestim (Pfizer) |
1 March 2019 | 1 May 2019 | 1 August 2019 | Zarzio (Novartis) |
| Filgrastim | Inj 480 mcg per 0.5 ml prefilled syringe, 10 prefileld syringe | $432.00 (per 5 prefilled syringe) |
$161.50 | Nivestim (Pfizer) |
1 March 2019 | 1 May 2019 | 1 August 2019 | Zarzio (Novartis) |
| Moclobemide | Tab 150 mg, 60 tablet blsiter pack | $85.10 (per 500 tab) |
$6.40 | Aurorix (Mylan) |
1 February 2019 | 1 April 2019 | 1 July 2019 | Apo-Moclobemide (Apotex) |
| Moclobemide | Tab 300 mg, 60 tablet blister pack | $30.70 (per 100 tab) |
$9.80 | Aurorix (Mylan) |
1 February 2019 | 1 April 2019 | 1 July 2019 | Apo-Moclobemide (Apotex) |
| Sodium fusidate [fusidic acid] | Crm 2%, 5 g tube OP | $2.52 (per 15 g) |
$1.59 | Foban (AFT) |
1 March 2019 | n/a | 1 August 2019 | DP Fusidic Acid Cream (15 g) (AFT) |
| Sodium fusidate [fusidic acid] | Oint 2%, 5 g tube OP | $3.45 (per 15 g) |
$1.59 | Foban (AFT) |
1 March 2019 | n/a | 1 August 2019 | Foban (15 g) (AFT) |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current pack price | New pack price | Hospital supply brand (Supplier) |
DV Limit |
Listing date | Hospital Supply Status date | Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
| Filgrastim | Inj 300 mcg in 0.5 ml prefilled syringe, 10 prefilled syringe | $270.00 (per 5 prefilled syringe) |
$96.22 | Nivestim (Pfizer) |
1% | 1 March 2019 | 1 May 2019 | Zarzio (Novartis) |
| Filgrastim | Inj 480 mcg in 0.5 ml prefilled syringe, 10 prefilled syringe | $432.00 (per 5 prefilled syringe) |
$161.50 | Nivestim (Pfizer) |
1% | 1 March 2019 | 1 May 2019 | Zarzio (Novartis) |
| Moclobemide | Tab 150 mg, 60 tablet blister pack | $85.10 (per 500 tab) |
$6.40 | Aurorix (Mylan) |
1% | 1 February 2019 | 1 April 2019 | Apo-Moclobemide (Apotex) |
| Moclobemide | Tab 300 mg, 60 tablet blister pack | $30.70 (per 100 tab) |
$9.80 | Aurorix (Mylan) |
1% | 1 February 2019 | 1 April 2019 | Apo-Moclobemide (Apotex) |
| Sodium fusidate [fusidic acid] | Crm 2%, 5 g tube | $2.52 (per 15 g) |
$1.59 | Foban (AFT) |
1% | 1 March 2019 | 1 May 2019 | DP Fusidic Acid Cream (15 g) (AFT) |
| Sodium fusidate [fusidic acid] | Oint 2%, 5 g tube | $3.45 (per 15 g) |
$1.59 | Foban (AFT) |
1% | 1 March 2019 | 1 May 2019 | Foban (15 g) (AFT) |
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
- the 2016/17 Invitation to Tender, dated 3 November 2016, and
- the 2017/18 Invitation to Tender, dated 2 November 2017.
2016/17 Invitation to Tender
| Chemical name | Line item |
|---|---|
| Bupivacaine hydrochloride with adrenaline | Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml sterile pack |
| Bupivacaine hydrochloride with adrenaline | Inj 5 mg per ml with adrenaline 1:200,000, 20 ml sterile pack |
| Metoclopramide hydrochloride | Inj 5 mg per ml, 2 ml ampoule |
| Trimethorpiem with sulphamethoxazole [Co-trimoxazole] |
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml |
2017/18 Invitation to Tender
| Chemical name | Line item |
|---|---|
| Ferrous sulphate with ascorbic acid | Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg |
| Filgrastim | Inj 120 mcg per ml, 0.5 ml prefileld syringe |
For products included in the 2016/17 and 2017/18 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.